Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Summit Therapeutics Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.79 (market cap $2.98B), while Summit Therapeutics Inc trades at $17.54 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 4.6× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Summit Therapeutics Inc for 16 Days on average.
| FNGU | SMMT | |
|---|---|---|
Market Cap | $2.98B | $13.71B |
Volume | 4,682,352 | 6,173,057 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $26.38 |
52-Week Low | $13.73 | $12.43 |
Typical Hold Time | 19 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.62, down 1.56% today. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. The ETN provides triple exposure to tech giants like Nvidia, Meta, and Apple, but carries significant volatility risks as highlighted by recent analysis showing an 87% decline during previous tech sector downturns.
The outlook remains highly speculative given the leveraged structure. While bullish technicals suggest potential upside if tech stocks continue performing, the extreme volatility and historical drawdowns present substantial risk. Investors should weigh the amplified returns against the possibility of rapid losses during market corrections.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
